AstraZeneca to buy RSV vaccine maker Icosavax for $1.1 bln
12/12/2023 07:11
Dec 12 (Reuters) - Drugmaker AstraZeneca AZN.L on Tuesday agreed to buy vaccine developer Icosavax ICVX.O in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio. (Reporting by Yadarisa Shabong in Bengaluru; Editing by Sonia Cheema) ((Yadarisa.Shabong@thomsonreuters.com; +91 9742735150;))
Recent news on Icosavax
See all newsU.S. RESEARCH ROUNDUP- Adobe, Costco Wholesale, Synopsys
Press Digest: British Business - Dec. 13
Brief: Icosavax Required To Pay Astrazeneca Finance And Holdings Termination Fee Of $27.2 Mln
Deals of the day-Mergers and acquisitions
France, Germany shares hit record highs, but give up gains after U.S CPI (updated)